Acurx Pharmaceuticals Inc (ACXP)
2.16
-0.09
(-4.00%)
USD |
NASDAQ |
May 16, 16:00
2.16
0.00 (0.00%)
After-Hours: 20:00
Acurx Pharmaceuticals Research and Development Expense (Quarterly): 1.555M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.555M |
| December 31, 2023 | 1.943M |
| September 30, 2023 | 1.349M |
| June 30, 2023 | 1.736M |
| March 31, 2023 | 1.016M |
| December 31, 2022 | 1.433M |
| September 30, 2022 | 1.591M |
| June 30, 2022 | 0.9117M |
| March 31, 2022 | 0.8189M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.7162M |
| September 30, 2021 | 1.127M |
| June 30, 2021 | 0.0951M |
| March 31, 2021 | 0.0919M |
| December 31, 2020 | 0.4575M |
| September 30, 2020 | 0.66M |
| June 30, 2020 | 0.4007M |
| March 31, 2020 | 0.6847M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.0919M
Minimum
Mar 2021
1.943M
Maximum
Dec 2023
0.9756M
Average
0.9117M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 17.12M |
| Seelos Therapeutics Inc | 5.918M |
| PetVivo Holdings Inc | 0.2311M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 5.554M |